SCHEMBL6497249

SCHEMBL6497249

O=C(N[C@@H]1C[C@H]2CCN(C2)C1)c1ccc(Cl)o1

nearest known ligand 0.63

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CHRNA7 P36544 9/20 0.63
HPGD P15428 2/20 0.44
ALDH1A1 P00352 1/20 0.43
TSHR P16473 1/20 0.43
CHRNB2 P17787 3/20 0.42
CHRNB4 P30926 3/20 0.42
CHRNA3 P32297 3/20 0.42
CHRNA4 P43681 3/20 0.42
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.40
CSF1R P07333 1/20 0.39
HTR3A P46098 1/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6497255 1.00 CHRNA7 (0.63) CHRNA7HPGDALDH1A1TSHRCHRNB2
SCHEMBL6488541 0.87 HPGD (0.60) CHRNA7HPGDALDH1A1TSHRCHRNB2
SCHEMBL6488534 0.87 HPGD (0.60) CHRNA7HPGDALDH1A1TSHRCHRNB2
SCHEMBL6486371 0.85 HPGD (0.59) CHRNA7HPGDALDH1A1TSHRCHRNB2
SCHEMBL6486376 0.85 HPGD (0.59) CHRNA7HPGDALDH1A1TSHRCHRNB2
SCHEMBL6497296 0.83 CHRNA7 (0.65) CHRNA7HPGDALDH1A1NPC1RAB9A
SCHEMBL6497302 0.83 CHRNA7 (0.65) CHRNA7HPGDALDH1A1NPC1RAB9A
SCHEMBL6487952 0.82 RAB9A (0.54) CHRNA7HPGDALDH1A1NPC1RAB9A
SCHEMBL6487956 0.82 RAB9A (0.54) CHRNA7HPGDALDH1A1NPC1RAB9A
SCHEMBL6487632 0.81 CHRNA7 (0.52) CHRNA7HPGDALDH1A1CHRNB2CHRNA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6919359-B2 Azabicyclic-substituted-heteroaryl compounds for the treatment of disease PFIZER INC (US) 2005-07-19 US claimed
US-20030207913-A1 Azabicyclic-substituted-heteroaryl compounds for the treatment of disease PHARMACIA & UPJOHN COMPANY 2003-11-06 US claimed
US-6919359-B2 Azabicyclic-substituted-heteroaryl compounds for the treatment of disease PFIZER INC (US) 2005-07-19 US disclosed
US-20030207913-A1 Azabicyclic-substituted-heteroaryl compounds for the treatment of disease PHARMACIA & UPJOHN COMPANY 2003-11-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030207913-A1 Azabicyclic-substituted-heteroaryl compounds for the treatment of disease MALT1, WFS1, NR5A1 CHRNA7 1097/4885HPGD 706/4885ALDH1A1 625/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.